Published in J Infect Dis on November 01, 1977
Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci U S A (1984) 4.56
Human cytomegalovirus productively infects primary differentiated macrophages. J Virol (1991) 3.16
Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev (2002) 2.86
Disseminated cytomegalovirus infection. Molecular analysis of virus and leukocyte interactions in viremia. J Clin Invest (1988) 2.05
Comparison of rates of virus isolation from leukocyte populations separated from blood by conventional and Ficoll-Paque/Macrodex methods. J Clin Microbiol (1979) 2.04
High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients. J Clin Invest (1992) 1.62
Comparison of five methods of cytomegalovirus antibody screening of blood donors. J Clin Microbiol (1983) 1.53
Growth kinetics of human cytomegalovirus are altered in monocyte-derived macrophages. J Virol (1995) 1.52
Mechanisms of cytomegalovirus-mediated myelosuppression: perturbation of stromal cell function versus direct infection of myeloid cells. Proc Natl Acad Sci U S A (1990) 1.49
Replication of human cytomegalovirus in human peripheral blood T cells. J Virol (1986) 1.45
Steady-state plasma membrane expression of human cytomegalovirus gB is determined by the phosphorylation state of Ser900. J Virol (1998) 1.29
Detection of murine cytomegalovirus DNA in circulating leukocytes harvested during acute infection of mice. J Virol (1989) 1.14
Pneumocystis pneumonia--Los Angeles. 1981. Am J Public Health (2006) 1.12
Acute cytomegalovirus infection and the host immune response. II. Relationship of suppressed in vitro lymphocyte reactivity to bacterial recall antigens and mitogens with the development of cytomegalovirus-induced lymphocyte reactivity. Clin Exp Immunol (1980) 1.04
Detection of cytomegalovirus from blood leukocytes separated by sepracell-MN and Ficoll-Paque/Macrodex methods. J Clin Microbiol (1988) 0.97
Utility of major leukocyte subpopulations for monitoring secondary cytomegalovirus infections in renal-allograft recipients by PCR. J Clin Microbiol (1998) 0.96
Susceptibility of lymphoblastoid cells to infection with human cytomegalovirus. Infect Immun (1979) 0.95
Lymphocyte subsets and natural killer cell responses during cytomegalovirus mononucleosis. Infect Immun (1983) 0.92
Bench-to-bedside review: rare and common viral infections in the intensive care unit--linking pathophysiology to clinical presentation. Crit Care (2008) 0.90
Cytomegalovirus infection in infancy: virological and immunological studies. Clin Exp Immunol (1982) 0.88
In situ hybridization for cytomegalovirus DNA in AIDS patients. Am J Pathol (1988) 0.86
Enhanced shedding of cytomegalovirus in semen of human immunodeficiency virus-seropositive homosexual men. J Clin Microbiol (1992) 0.86
Persistent infection of human lymphoid and myeloid cell lines with herpes simplex virus. Infect Immun (1979) 0.86
Herpesvirus sylvilagus infects both B and T lymphocytes in vivo. J Virol (1985) 0.84
Role of primary and secondary maternal viremia in transplacental guinea pig cytomegalovirus transfer. J Virol (1990) 0.84
Potential of in situ hybridization for early diagnosis of productive cytomegalovirus infection. J Clin Microbiol (1988) 0.83
Neutrophil response and function during acute cytomegalovirus infection in guinea pigs. Infect Immun (1982) 0.83
Infectious center assay of intracellular virus and infective virus titer for equine mononuclear cells infected in vivo and in vitro with equine herpesviruses. Can J Comp Med (1983) 0.81
Immediate loss of cell-mediated immunity to murine cytomegalovirus upon treatment with immunosuppressive agents. Infect Immun (1980) 0.81
Low Interferon Relative-Response to Cytomegalovirus Is Associated with Low Likelihood of Intrauterine Transmission of the Virus. PLoS One (2016) 0.79
Bone marrow atrophy induced by murine cytomegalovirus infection. Immunology (1994) 0.79
Pulmonary macrophage function during experimental cytomegalovirus interstitial pneumonia. Infect Immun (1985) 0.78
Longitudinal studies of cytomegalovirus-specific cell-mediated immunity in congenitally infected infants. Infect Immun (1983) 0.77
The cellular immune response to cell-associated and cell-free cytomegalovirus (CMV) antigens after primary CMV-infection in non-immunocompromised hosts: development and maintenance of CMV-latency and its influence on immunocompetence. Clin Exp Immunol (1988) 0.76
Comparison of the Histopaque-1119 method with the Plasmagel method for separation of blood leukocytes for cytomegalovirus isolation. J Clin Microbiol (1992) 0.75
Pneumocystis lung disease in homosexual men. West J Med (1982) 0.75
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol (1987) 17.36
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med (1995) 6.90
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med (1996) 5.96
Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest (1986) 5.90
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol (1987) 5.03
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 4.58
HTLV-III in the semen and blood of a healthy homosexual man. Science (1984) 4.53
Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med (1986) 4.37
Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study. Lancet (1987) 4.33
Macrophages and age-dependent resistance to Herpes simplex virus in mice. J Immunol (1970) 4.15
Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med (1996) 4.13
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis (2000) 3.73
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature (1993) 3.73
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol (1981) 3.71
Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet (1985) 3.50
Selective effects of anti-macrophage serum, silica and anti-lymphocyte serum on pathogenesis of herpes virus infection of young adult mice. J Immunol (1970) 3.49
The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med (1992) 3.32
HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science (1988) 3.12
Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet (1985) 3.03
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
Stimulation of DNA synthesis in mouse cell line 3T3 by Simian virus 40. Proc Natl Acad Sci U S A (1966) 2.81
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med (1995) 2.66
Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med (1981) 2.56
Transformation of primary rat embryo cells by adenovirus type 2. Proc Natl Acad Sci U S A (1967) 2.53
Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science (1987) 2.51
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1990) 2.50
Opportunistic lung infection due to "Pittsburgh Pneumonia Agent". N Engl J Med (1979) 2.49
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother (1987) 2.47
New bacterial agent of pneumonia isolated from renal-transplant recipients. Lancet (1979) 2.45
Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells. Transfusion (1985) 2.45
Human immunodeficiency virus type 1 (HIV-1) infection a median of 18 months before a diagnostic western blot. Evidence from a cohort of homosexual men. Ann Intern Med (1989) 2.44
Mechanisms of immunosuppression in cytomegaloviral mononucleosis. J Infect Dis (1980) 2.41
Primary human T-lymphotropic virus type III infection. Ann Intern Med (1985) 2.40
Contact-inhibited revertant cell lines isolated from SV 40-transformed cells. IV. Microfilament distribution and cell shape in untransformed, transformed, and revertant Balb-c 3T3 cells. J Cell Biol (1973) 2.40
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA (1989) 2.38
Immunohistochemical identification of HTLV-III antigen in brains of patients with AIDS. Ann Neurol (1986) 2.37
Transformation of mouse cell line 3T3 by SV40: dose response relationship and correlation with SV40 tumor antigen production. Virology (1966) 2.34
Immunopathology of lymphocytic choriomeningitis viurs infection of newborn mice. Antithymocyte serum effects on glomerulonephritis and wasting disease. J Exp Med (1968) 2.31
Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene (2009) 2.27
Variables influencing condom use in a cohort of gay and bisexual men. Am J Public Health (1988) 2.26
Comparative studies on the carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. II. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry (1969) 2.24
Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1994) 2.24
Loss of human immunodeficiency virus type 1 (HIV-1) antibodies with evidence of viral infection in asymptomatic homosexual men. A report from the Multicenter AIDS Cohort Study. Ann Intern Med (1988) 2.18
Human immunodeficiency virus (HIV) infection of the uterine cervix. Ann Intern Med (1988) 2.17
Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr (2000) 2.13
The effect of interferon on SV-40 T antigen production in SV-40-transformed cells. Virology (1967) 2.13
Viability and recovery of peripheral blood mononuclear cells cryopreserved for up to 12 years in a multicenter study. Clin Diagn Lab Immunol (1999) 2.11
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med (1997) 2.06
Viability and functional activity of cryopreserved mononuclear cells. Clin Diagn Lab Immunol (2000) 2.05
Coalescent estimates of HIV-1 generation time in vivo. Proc Natl Acad Sci U S A (1999) 2.02
Sexual transmission efficiency of hepatitis B virus and human immunodeficiency virus among homosexual men. JAMA (1990) 2.00
Risk of nosocomial infection with human T-cell lymphotropic virus III (HTLV-III). N Engl J Med (1985) 1.99
Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS. Lancet (1986) 1.96
Contact-inhibited revertant cell lines isolated from SV40-transformed cells. II. Ultrastructural study. J Cell Biol (1971) 1.96
Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis (1991) 1.93
Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med (1998) 1.88
Nucleic acid homology studies of SV 40 virus-transformed and normal hamster cells. Proc Natl Acad Sci U S A (1966) 1.87
Effects of anti-lymphoid sera on viral infections. Lancet (1968) 1.87
Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother (1996) 1.86
Activation of leukemia viruses by graft-versus-host and mixed lymphocyte reactions in vitro. Proc Natl Acad Sci U S A (1972) 1.85
Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med (1979) 1.83
Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Ann Intern Med (1985) 1.83
Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions. J Infect Dis (1981) 1.81
Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. J Infect Dis (1988) 1.81
AIDS prevention in homosexual and bisexual men: results of a randomized trial evaluating two risk reduction interventions. AIDS (1989) 1.80
Contact-inhibited revertant cell lines isolated from simian virus 40-transformed cells. 3. Concanavalin A-selected revertant cells. J Virol (1972) 1.79
Infrequency of isolation of HTLV-III virus from saliva in AIDS. N Engl J Med (1985) 1.78
Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med (1981) 1.77
Infection of human endothelial cells by human T-lymphotropic virus type I. Proc Natl Acad Sci U S A (1984) 1.73
Effects of anti-thymocyte serum on lymphocytic choriomeningitis (LCM) virus infection in mice. Proc Soc Exp Biol Med (1967) 1.71
Replication of herpes simplex virus and cytomegalovirus in human leukocytes. J Immunol (1978) 1.69
The oncogenic DNA viruses: a review of in vitro transformation studies. Annu Rev Microbiol (1968) 1.69
Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. Proc Natl Acad Sci U S A (1996) 1.68
No association between herpes simplex virus type-2 seropositivity or anogenital lesions and HIV seroconversion among homosexual men. J Acquir Immune Defic Syndr (1990) 1.67
Adenovirus type 12-rat embryo transformation system. J Virol (1967) 1.67